News|Articles|November 16, 2026

FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Labeling permits home self-administration or use under clinician supervision for acute agitation in adults with schizophrenia-spectrum or bipolar disorders, addressing a prior gap requiring facility-based management.
  • SERENITY III supported at-home use via primary safety/tolerability outcomes across 1160 self-treated episodes in 102 patients, with consistent tolerability on repeat dosing.
SHOW MORE

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder can now self-administer dexmedetomidine sublingual film (Igalmi; Teva) at home to treat acute agitation, making it the first FDA-approved option for this use, according to Teva Pharmaceuticals.1 The company announced the approval on November 16, 2026.

What the Approval Covers

Dexmedetomidine sublingual film is a highly selective α2-adrenergic receptor agonist placed under the tongue or between the lower lip and gum. The label supports use at home and under health care provider supervision. Safety in children has not been established.

The FDA first approved dexmedetomidine in April 2022 for agitation associated with schizophrenia or bipolar I or II disorder, based on the SERENITY I (NCT04268303) and II (NCT04276883) trials.2

Teva said no FDA-approved treatment was previously indicated for patient self-administration at home during an agitation episode, and that existing options generally require a health care setting or provider supervision.1 The supplemental new drug application for at-home use was submitted January 14, 2026, and Teva acquired dexmedetomidine sublingual film in late October 2026. The company has not yet announced commercialization plans for at-home use.

Phase 3 Data Support At-Home Safety

Approval for at-home use rests on SERENITY III (NCT05658510), a randomized, double-blind, placebo-controlled phase 3 study that ran for 12 weeks.1,3 The trial was sponsored by BioXcel Therapeutics, according to the trial registry.3 Teva reported that 102 patients receiving dexmedetomidine sublingual film treated 1160 agitation episodes with a self-administered study drug outside a health care setting.1

The primary end point was safety and tolerability, which Teva reported was met. Tolerability was consistent with repeat dosing, and no patients discontinued because of tolerability.

The most common adverse events in the at-home trial, occurring in at least 5% of patients and more often than with placebo, were somnolence, dry mouth, dizziness, and oral paresthesia or hypoesthesia.

Supervised Trials Showed Reduced Agitation

Efficacy data come from the SERENITY I and II randomized, double-blind, placebo-controlled, fixed-dose phase 3 studies, conducted under health care supervision.1,2 SERENITY I randomized 380 patients with schizophrenia or schizoaffective disorder, and SERENITY II enrolled 378 patients with bipolar disorder.2,4 The primary end point was change in agitation measured by the Positive and Negative Syndrome Scale Excited Component (PEC) score.1,4

In SERENITY I, the 120 μg dose reduced PEC scores by 8.5 points at 2 hours, compared with 4.8 points with placebo, a least squares mean difference of −3.7 points (97.5% CI, −4.9 to −2.5; P < .001).4 The 180 μg dose reduced scores by 10.3 points. Teva reported that some effects appeared as early as 20 minutes after dosing.1

Dexmedetomidine sublingual film carries risks of low blood pressure, orthostatic hypotension, and slow heart rate. Patients are advised to drink fluids, sit or lie down after dosing, and stand up slowly.

Caution is warranted in patients with heart problems, bradycardia, hypotension, chronic hypertension, a history of fainting, hypovolemia, diabetes, low potassium or magnesium, liver problems, or age 65 years or older. Safety in pregnancy and breastfeeding has not been established, and concomitant blood pressure or heart medicines and sedating drugs such as opioids call for caution.

Agitation Often Escalates to Emergency Care

"With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it," Chris Fox, executive vice president of US Commercial and head of Innovative Franchise at Teva, said in a statement.

According to Teva, agitation affects 25% to 40% of people with these conditions and can include tension, restlessness, and increased activity. Episodes escalate to emergency care or hospitalization in up to 21% of cases.

"Innovation in neuroscience is about discovering new medicines and also about rethinking when, where, and how treatment can be delivered," Eric Hughes, MD, PhD, executive vice president of Global R&D and chief medical officer at Teva, said in the statement. "The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes."

References

1. U.S. FDA approves Igalmi as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. News release. Teva Pharmaceuticals. November 16, 2026. Accessed November 16, 2026. https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-schizophrenia-s

2. Zagorski N. FDA Approves Igalmi for Agitation. Psychiatric News. 2022;57(5). doi:10.1176/appi.pn.2022.05.5.10

3. Dexmedetomidine in the treatment of agitation associated with schizophrenia and bipolar disorder (SERENITY III). ClinicalTrials.gov identifier: NCT05658510. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT05658510

4. Citrome L, Preskorn SH, Lauriello J, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2022;83(6):22m14447. doi:10.4088/JCP.22m14447


Related to this article